Artery Therapeutics

• Jan Johansson

Sources: reporter.nih.gov

• National Institute on Aging

  R44, Subcutaneous CS6253 9-Month Chronic Toxicology GLP Study in Cynomolgus Monkeys to assess Safety, Tolerability and PK, R44AG099463, US$2.3m, 2026–2028, 17 Sept 2026

• National Institute on Aging

  UG3, CS6253 Sequential Subcutaneous Pharmacokinetic Study followed by Phase 2A Placebo-Controlled Trial with Three Fixed Doses in APOE4 MCI and AD Patients to assess Safety, PK, and Biomarker Effects, UG3AG098023, US$2.6m, 2026–2028, 3 Mar 2026

Sources: reporter.nih.gov

• Air pollution is associated with sex-specific longitudinal changes in astrocytic and neuroinflammatory processes linked to cognitive decline in Alzheimer's disease at-risk individuals

  Consulting or advice, Board or leadership role, 1 Oct 2026

• Evoke (+) trials of semaglutide for early alzheimer's disease: Innovations, lessons, and implications

  Consulting or advice, 24 Sept 2026

• Epitope placement tunes CSF tau biomarkers: Comparison of P-tau217 and BD-tau designs

  Consulting or advice, Board or leadership role, 22 Sept 2026

• Circulating Metabolite Signatures Associated With Amyloid Positivity, Cognitive Performance and Plasma P-tau181 Levels in Cognitively Unimpaired Older Adults

  Consulting or advice, Board or leadership role, 14 Sept 2026

• Matrix metalloproteinase-9 is associated with CX3CL1 on tau and amyloid biomarker pathways in APOE4 carriers

  Consulting or advice, Board or leadership role, 13 Sept 2026

• Parental longevity and polygenic longevity scores in relation to ageing-related factors in a population of 70-year-olds followed over six years: The Gothenburg H70 Birth Cohort Study

  Consulting or advice, Board or leadership role, 11 Sept 2026

• Blood-based biomarkers of Alzheimer's disease and neurodegeneration in an indigenous African cohort using both Simoa and NULISA platforms

  Consulting or advice, Board or leadership role, 2 Sept 2026

• Incidence of dementia and mild cognitive impairment in two Indigenous Bolivian cohorts

  Consulting or advice, Board or leadership role, 1 Sept 2026

• Presymptomatic plasma biomarkers in autosomal dominant Alzheimer's disease: sequence and timing

  Consulting or advice, Board or leadership role, 24 Aug 2026

• Cognitive components derived from traditional neuropsychological tests and their associations with plasma p-tau217 and p-tau181 in mild cognitive impairment: a multisite analysis

  Consulting or advice, Board or leadership role, 12 Aug 2026

• Prediction of mild cognitive impairment progression using time-sensitive multimodal biomarkers

  Consulting or advice, Board or leadership role, 12 Aug 2026

• Plasma Biomarkers for Neocortical Tau Burden

  Consulting or advice, Fees or honoraria, Board or leadership role, 10 Aug 2026

• Lifestyle and psychosocial protective factors drive healthy aging and modulate inflammatory and metabolic pathways

  Consulting or advice, Board or leadership role, 5 Aug 2026

• Astrocyte reactivity modifies the effects of locus coeruleus norepinephrine-related dysfunction on tau and its impact on cognition

  Consulting or advice, Board or leadership role, 1 Aug 2026

• Predicting continuous amyloid PET levels with CSF and plasma brain-derived p-tau217

  Consulting or advice, Board or leadership role, 1 Aug 2026

• CSF fibrinogen predicts longitudinal Tau accumulation in cognitively unimpaired older adults

  Consulting or advice, Board or leadership role, 1 Aug 2026

• Interpreting p-tau217 on the ward: frailty and plasma biomarkers in acutely admitted older adults

  Consulting or advice, Board or leadership role, 1 Aug 2026

• Age-related alterations in plasma biomarkers of relevance to Alzheimer's disease are attenuated in KLOTHO KL-VS heterozygotes

  Consulting or advice, Board or leadership role, 6 Mar 2026

• Unraveling the role of polyamine metabolism in postoperative delirium: insights into biochemical mechanisms and biomarker potential

  Consulting or advice, Board or leadership role, 21 Feb 2026

• Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders

  Shares or equity, 19 Dec 2025

Sources: pubmed.ncbi.nlm.nih.gov